top of page

Liang Zhao

Visiting PhD Student

Notable Publications:


Here are the references rewritten in the specified format:

Zhao L, Pang Y, Zhou Y, et al. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. Signal Transduct Target Ther, 2024. doi:10.1038/s41392-024-01853-w.


Zhao L, Kang F, Pang Y, et al. Fibroblast activation protein inhibitor tracers and their preclinical, translational, and clinical status in China. J Nucl Med, 2024;65(Suppl 1):4S-11S. doi:10.2967/jnumed.123.266983.


Zhao L, Pang Y, Fang J, et al. Design, preclinical evaluation, and clinical translation of [68Ga]Ga-FAPI-LM3, a heterobivalent molecule for PET imaging of nasopharyngeal carcinoma. J Nucl Med, 2024;65(3):394-401. doi:10.2967/jnumed.123.266183.


Zhao L, Wen X, Xu W, et al. Clinical evaluation of [68Ga]Ga-FAPI-RGD for imaging of fibroblast activation protein and integrin αvβ3 in various cancer types. J Nucl Med, 2023;64(8):1210-1217. doi:10.2967/jnumed.122.265383.


Zhao L, Pang Y, Chen S, et al. Prognostic value of fibroblast activation protein expressing tumor volume calculated from [68Ga]Ga-FAPI PET/CT in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging, 2023;50(2):593-601. doi:10.1007/s00259-022-05989-1.


Zhao L, Chen J, Pang Y, et al. Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review. Theranostics, 2022;12(4):1557-1569. doi:10.7150/thno.69475.


Zhao L, Niu B, Fang J, et al. Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of [68Ga]Ga-labeled FAPI dimer. J Nucl Med, 2022;63(6):862-868. doi:10.2967/jnumed.121.263016.

Liang Zhao
bottom of page